Approximately 50% of people with chronic whiplash-associated disorders (WAD) continue to report the presence of symptoms 12 months post-injury. These symptoms include high levels of pain and disability as well as psychological symptoms such as post-traumatic stress. The nervous system may also be affected, specifically the autonomic nervous system which is responsible for regulating heart rate and blood pressure. An important part of the autonomic system is the vagus nerve, which helps regulate pain and stress responses. Treatment of this nerve via transauricular vagal nerve stimulation (taVNS) has been shown to improve health outcomes in many pain conditions such as chronic low back pain and postural tachycardia syndrome. TaVNS works by sending mild electrical pulses through the ear. This project aims to explore whether or not taVNS can help people with chronic whiplash-associated disorders (WAD) feel better. The first goal is to evaluate the safety and feasibility of taVNS. The investigators are interested in learning how many people with chronic WAD participate in the study and how many complete the full treatment, as well as ensuring that the treatment does not cause any serious side effects. An additional goal is to evaluate the effects of taVNS on neck pain intensity and associated disability, pain sensitivity, heart rate variability, blood pressure, quality of life, post-traumatic stress, stress, anxiety, and depression as measured by questionnaires and physical assessments, as compared to those assigned to the sham treatment.
Approximately 50% of people with chronic whiplash-associated disorders (WAD) continue to report the presence of symptoms 12 months post-injury. Many of these patients present with high levels of pain and disability and a heterogeneous presentation of both physical and psychological manifestations, inclusive of central nervous system hyperexcitability. Autonomic dysfunction has also been demonstrated in WAD. Autonomic dysregulation via impaired peripheral vasoconstrictor responses has been demonstrated in both acute and chronic WAD, although the association with clinical features and health outcomes is unclear. Dysregulation of the hypothalamic-pituitary-adrenal axis (one of the key pathways to respond to stress) via reduced reactivity and enhanced negative feedback suppression has also been demonstrated in chronic WAD. In association with high levels of psychological distress and post-traumatic stress symptoms, stress system dysfunction in the form of autonomic nervous system (ANS) dysregulation is possible. Previous resaerch by the investigators has demonstrated changes in autonomic function through heart rate and blood pressure measures in chronic WAD. More recently, the role of the ANS in chronic WAD has been examined using pupillometry. The results showed the presence of increased sympathetic nervous system activity, and reduced parasympathetic activity. These findings are consistent with those observed in other chronic pain conditions. This imbalance reportedly decreases the ANS adaptive response to both physical or emotional pain. These findings support the hypothesis that autonomic dysfunction potentially contributes to pain persistence. An important link between the autonomic system and pain regulation mechanisms is the vagus nerve. Pain control occurs through vagally mediated afferent and efferent stimuli. The vagus nerve is also known to carry around 75% of parasympathetic fibers. Treatments affecting vagally mediated pain control includes non-invasive vagus nerve stimulation (VNS). Transauricular VNS (taVNS) has been shown to improve health outcomes in many dysautonomic conditions and pain, such as chronic low back pain and postural tachycardia syndrome. Improvements in both biomarkers of autonomic dysfunction, such as heart rate variability (HRV); in association with reductions of pain and disability and improvements in pain sensitivity have been demonstrated, illustrating the potential of tVNS to modulate pain. The specific objectives of this study are as follows: 1. The primary objective is to evaluate the safety and feasibility of a randomized pilot study of taVNS as a treatment for patients with WAD in terms of recruitment (greater than 30%), attendance (70% total treatment time in a 4 week period), retention (greater than 70% complete protocol), safety (no severe adverse events and less than a 30% increase in adverse effects for the active group), and acceptability of the protocol. 2. The secondary exploratory objectives are to evaluate neck pain intensity and associated disability, pain sensitivity, HRV, blood pressure, quality of life, post-traumatic stress, stress, anxiety, and depression - as measured by questionnaires and physical assessments - following active taVNS compared to sham taVNS in patients with WAD. This will be a randomized, sham-controlled, participant and assessor blinded, pilot trial evaluating the safety and feasibility of taVNS for the treatment of WAD symptoms. Consenting and eligible participants will be asked to complete baseline questionnaires, physicial measurements (height, weight, and BMI), and clinical measurements. Questionnaires and physical measurements will be repeated immediately 1 month post taVNS and at 8-10 \& 16 weeks. Participants will be be asked to refrain from taking prescribed medications, performing physical exercise, or consuming alcohol or coffee on day of testing. Blood pressure, heart rate variability, and pupillary light reflex measures will be performed. Participants will be instructed on use of a taVNS device including precautions and safety information. Following study enrolment, participants will be randomized into one of two groups: active taVNS or sham taVNS. Randomization will occur via a sealed envelope where participant numbers have been sorted into active or sham taVNS by a random number generator. Participants in the sham group will be blinded using a previously established blinding method. They will undergo a 30 second ramp up period, during which, the current will be gradually increased and then the machine will reduce the waveform to 0 whilst remaining in the 'on' mode. Assessors will be blinded to the participants grouping. Transauricular VNS will be administered using the Nurosym aVNT (auricular vagal neuromodulation therapy) Device (Parasym, London, UK). The Nurosym aVNT Device delivers non-invasive neuromodulation targeting the auricular branch of the vagus nerve via the tragus of the outer ear. All participants will receive four weeks of twice daily (morning and evening) 45-minute sessions of taVNS (frequency ≥ 25Hz; pulse width =250µs.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
40
Transauricular VNS will be administered using the Parasym aVNT (auricular vagal neuromodulation therapy) Device (Nurosym, London, UK). The Parasym aVNT Device delivers non-invasive neuromodulation targeting the auricular branch of the vagus nerve via the tragus of the outer ear. All participants will receive four weeks of twice daily (morning and evening) 45-minute sessions of taVNS (frequency ≥ 25Hz; pulse width =250µs (Fig). The safety and tolerability of taVNS has been demonstrated in seven studies with a total of 205 (116 active, 121 sham) cardiovascular patients. Stimulation protocols ranged from 43 min to 8 hrs daily, for 1 day to 6 months. There were no device-related serious adverse events. Three patients (1.5%) experienced minor adverse events, i.e., dermal paresthesias (light tingling at the ear). No differences in tolerability were observed between active and sham taVNS \[21\].
Vivo Cura Health
Calgary, Alberta, Canada
Number of participants with treatment-related adverse events (AEs); recruitment rate; attendance rate; retention rate.
The primary objective is to evaluate the safety and feasibility of a randomized pilot study of taVNS as a treatment for patients with WAD in terms of recruitment (greater than 30%), attendance (70% total treatment time in a 4 week period), retention (greater than 70% complete protocol), safety (no severe adverse events and less than a 30% increase in adverse effects for the active group), and acceptability of the protocol.
Time frame: The study duration is 4 months, including 1 month of self-administered taVNS. Outcome measures will be assessed at baseline, immediately post-treatment (end of week 4) and during follow-ups at Week 8-10 and Week 16.
Neck pain intensity as measured by the Numerical Pain Rating Scale, 0-10.
Neck pain intensity will be measured via the Numerical Pain Rating Scale (NPRS). This scale ranges from 0-10 with a higher score indicating more pain intensity.
Time frame: Outcome measures will be assessed at baseline, immediately post-treatment (end of week 4) and during follow-ups at Week 8-10 and Week 16.
Neck-related disability as measured by the Neck Disability Index, 0-50.
Neck-related disability will be measure by the Neck Disability Index. This test ranges betweeen a score of 0-50 with higher scores meaning increased severity of neck-related disability.
Time frame: Outcome measures will be assessed at baseline, immediately post-treatment (end of week 4) and during follow-ups at Week 8-10 and Week 16.
Pain sensitivity as measured by Pressure Pain Thresholds in Newtons.
Changes in pain sensitivity will be measured by assessing presure pain thresholds. An algometer will be placed on the leg or neck region and pressure will be increased until the moment when the sensation of pressure first becomes painful. At this point, the pressure will stop being applied and the value will be recorded in Newtons.
Time frame: Outcome measures will be assessed at baseline, immediately post-treatment (end of week 4) and during follow-ups at Week 8-10 and Week 16.
Temporal Summation as measured by NPRS, 0-10.
Temporal summation will be measured using a pin prick. The pin prick will be gently raised and lowered over the hand region, without piercing the skin, to the beat of a metronome - 1 every second. The pain will be recorded at various times at different intervals by utilizing the Numerical Pain Rating Scale (NPRS) which ranges from 0-10.
Time frame: Outcome measures will be assessed at baseline, immediately post-treatment (end of week 4) and during follow-ups at Week 8-10 and Week 16.
Sensitivity to pressure as measured by Conditioned Pain Modulation (% change from baseline).
Sensitivity to pressure will be measured by Conditioned Pain Modulation (CPM). A blood pressure cuff will by worn on the upper arm and the pressure will be increased until the pain experienced is 5/10. At that time, pressure will also be applied to the shin to test the sensitivity in this region. The pressure pain threshold (PPT) on the shin will be compared before and during the arm pain from the cuff. The change in sensitivity will be recorded as a percentage of the baseline value. A lower pressure senstivity during the cuff main indicates suggests better pain tolerance. Pain inhibition is indicated if the percentage is negative.
Time frame: Outcome measures will be assessed at baseline, immediately post-treatment (end of week 4) and during follow-ups at Week 8-10 and Week 16.
Heart rate variability (RMSSD in ms).
Heart rate variability (HRV) will be measured via HRV4Training app and the root mean square of successive differences (RMSSD) will be recorded in ms. RMSSD is a measure of HRV which calculats the variability of the heart rate in one minute.
Time frame: Outcome measures will be assessed at baseline, immediately post-treatment (end of week 4) and during follow-ups at Week 8-10 and Week 16.
Blood pressure recorded in mmHg.
Blood pressure will be recorded while seated using a standard arm cuff (sphygmomanometer).
Time frame: Outcome measures will be assessed at baseline, immediately post-treatment (end of week 4) and during follow-ups at Week 8-10 and Week 16.
Quality of life as measured by SF-12.
Quality of life will be evaluated using the Short Form-12 (SF-12) questionnaire which measures both a physical component summary (PCS0) and mental component summary (MCS) score. Higher scores reflect better health status.
Time frame: Outcome measures will be assessed at baseline, immediately post-treatment (end of week 4) and during follow-ups at Week 8-10 and Week 16.
PTSD symptoms as measured by the PCL-5.
PTSD symptoms will be assesed using the PCL-5 questionnaire. This questionnaire consists of 20 questions reflecting DSM-5 PTSD criteria. The answer to each question is rated 0-4 with the total score ranging from 0-20. Higher scores indicated increased PTSD symptom severity.
Time frame: Outcome measures will be assessed at baseline, immediately post-treatment (end of week 4) and during follow-ups at Week 8-10 and Week 16.
Depression, anxiety, and stress via DASS-21.
Changes in depression, anxiety, and stress will be measured using the DASS-21 questionniare consisting of 21 questions measuring symptoms of each condition. Each question can be rated on a 4-point Likert scale. Scores for each of the three subscales (7 questions each) are summed and multiplied by 2 to give a final score for each condition ranging from 0-42. Higher scores indicated increased symptom severity for each condition.
Time frame: Outcome measures will be assessed at baseline, immediately post-treatment (end of week 4) and during follow-ups at Week 8-10 and Week 16.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.